Key exclusion criteria include short life expectancy (<24 h), SBP <95 mm Hg and/or needing inotropic medication or mechanical circulatory support at screening, T1DM, treatment in the last 14 days or under treatment with anti-immunological drugs for COVID-19, DKA history in the prior 6 months or treatment with any SGLT2 inhibitors at screening or within the prior 4 weeks. This evidence concerns the gene SLC5A2 and COVID-19.